Detalles de la búsqueda
1.
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study.
BMC Cancer
; 22(1): 915, 2022 Aug 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35999527
2.
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
Oncologist
; 26(10): e1854-e1861, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34101934
3.
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study).
Sci Rep
; 13(1): 1257, 2023 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36690734
4.
Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab.
Clin Kidney J
; 16(9): 1465-1468, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37664578
5.
Sexual function and sex hormones in breast cancer patients.
Endocrine
; 60(3): 510-515, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29138989
6.
Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
Lung Cancer Manag
; 9(1): LMT22, 2020 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32256708
Resultados
1 -
6
de 6
1
Próxima >
>>